Revenue grew 10% to $12.6m in FY25, with EBITDA up 26% and net profit rising to $0.8m. Ongoing patent negotiations and regulatory progress in China position the business for continued growth amid strong demand for probiotics.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.